# Phase IIa Study of Pharmacokinetics, Safety and Efficacy of QY201 Tablets in Adolescent Subjects With Moderate to Severe Atopic Dermatitis

> **NCT07712536** · PHASE2 · COMPLETED · sponsor: **E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.** · enrollment: 24 (actual)

## Conditions studied

- Adolescent Participants With Moderate to Severe Atopic Dermatitis (AD)

## Interventions

- **DRUG:** QY201 Tablets（10mg）
- **DRUG:** QY201 Tablets（20mg）

## Key facts

- **NCT ID:** NCT07712536
- **Lead sponsor:** E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-06-04
- **Primary completion:** 2025-12-19
- **Final completion:** 2025-12-19
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2026-07-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07712536

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07712536, "Phase IIa Study of Pharmacokinetics, Safety and Efficacy of QY201 Tablets in Adolescent Subjects With Moderate to Severe Atopic Dermatitis". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07712536. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*